Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has shared an update.
On December 17, 2025, Tiziana Life Sciences celebrated its advancements in biotechnology with its Founder and Executive Chairman, Gabriele Cerrone, ringing the Closing Bell at Nasdaq MarketSite in Times Square. The event highlighted the company’s progress, including dosing advancements in its clinical trials for intranasal foralumab, which offers an innovative approach to treating neurodegenerative and inflammatory diseases. This milestone reinforces Tiziana’s commitment to transforming patient care and solidifies its positioning as a leader in pioneering immunomodulation therapies.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies using transformational drug delivery technologies, including its patented intranasal approach. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody that has shown promising safety and efficacy in treating neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer’s disease, and ALS.
Average Trading Volume: 352,210
Technical Sentiment Signal: Buy
Current Market Cap: $184.2M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.